About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Reversibility of Methacholine Induced Bronchoconstriction

NCT05977699·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of Saskatchewan

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

age (years) at least 18, male or female
no confounding health issue (i.e. no health conditions, other than asthma, that would put the participant at risk or affect data integrity)
baseline FEV1 ≥ 65% predicted (per Quanjer GLI 2012)
methacholine PD20 ≤ 800mcg

You may not be if

respiratory infection within 4 weeks of Visit 1
exposure to triggers of respiratory symptoms within 4 weeks of Visit 1
currently pregnant or breastfeeding
current smoker (cigarettes, vaping)

The record

StatusCompleted

PhasePhase 4

Taking part16

StartedJan 2024

UpdatedMay 4, 2026

Conditions

Where1

Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall
Saskatoon, Saskatchewan, Canada

Clareo Health | Reversibility of Methacholine Induced Bronchoconstriction